Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Liabilities: 2010-2025

Historic Total Liabilities for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $355.3 million.

  • Myriad Genetics' Total Liabilities rose 1.63% to $355.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.3 million, marking a year-over-year increase of 1.63%. This contributed to the annual value of $326.5 million for FY2024, which is 10.13% down from last year.
  • Per Myriad Genetics' latest filing, its Total Liabilities stood at $355.3 million for Q3 2025, which was up 22.86% from $289.2 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Total Liabilities registered a high of $465.7 million during Q3 2023, and its lowest value of $262.8 million during Q2 2022.
  • Its 3-year average for Total Liabilities is $357.5 million, with a median of $349.6 million in 2024.
  • Per our database at Business Quant, Myriad Genetics' Total Liabilities slumped by 42.61% in 2022 and then soared by 71.99% in 2023.
  • Myriad Genetics' Total Liabilities (Quarterly) stood at $352.9 million in 2021, then dropped by 11.33% to $312.9 million in 2022, then grew by 16.11% to $363.3 million in 2023, then dropped by 10.13% to $326.5 million in 2024, then increased by 1.63% to $355.3 million in 2025.
  • Its last three reported values are $355.3 million in Q3 2025, $289.2 million for Q2 2025, and $301.2 million during Q1 2025.